{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:54:34Z","timestamp":1783814074508,"version":"3.55.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atypical chronic myeloid leukemia (aCML) is included in the group of myelodysplastic\/myeloproliferative neoplasms by the International Consensus Classification and has been renamed as MDS\/MPN with neutrophilia by the fifth edition of World Health Organization classification. It is always characterized by morphologic identification of granulocytic dysplasia with &amp;gt;10% circulating immature myeloid cells, 2 distinguished features that differentiate this disease among the others. Somatic mutations may help to diagnose but are not specifically pathognomonic of the disease, with the most detected including ASXL1, SETBP1, NRAS, KRAS, SRSF2, and TET2 and with low-frequency CBL, CSF3R, JAK2, and ETNK1. The genomic landscape of aCML has been recently unravelling, revealing that SETBP1 and ETNK1 are usually not ancestral but secondary events associated with disease progression. Unfortunately, until now, no consensus on risk stratification and treatment has been developed: Mayo Clinic prognostic score identified as adverse events age &amp;gt;67 years, hemoglobin level &amp;lt;10\u2009\u200ag\/dL, and TET2 mutations. Although some possible genetic markers have been identified, allogeneic transplant remains the only curative strategy.<\/jats:p>","DOI":"10.1182\/hematology.2023000448","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:56Z","timestamp":1702048316000},"page":"476-482","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Atypical CML: diagnosis and treatment"],"prefix":"10.1182","volume":"2023","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"7","key":"2023120815071758900_hem2023000448C1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"issue":"20","key":"2023120815071758900_hem2023000448C2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023120815071758900_hem2023000448C3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023120815071758900_hem2023000448C4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023120815071758900_hem2023000448C5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"11","key":"2023120815071758900_hem2023000448C6","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"17","key":"2023120815071758900_hem2023000448C7","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2023120815071758900_hem2023000448C8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Hern\u00e1ndez","year":"2000","journal-title":"Ann Oncol"},{"issue":"8","key":"2023120815071758900_hem2023000448C9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"2023120815071758900_hem2023000448C10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.26828","article-title":"Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Patnaik","year":"2023","journal-title":"Am J Hematol"},{"issue":"16","key":"2023120815071758900_hem2023000448C11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2023120815071758900_hem2023000448C12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"2023120815071758900_hem2023000448C13","doi-asserted-by":"crossref","first-page":"756348","DOI":"10.3389\/fonc.2021.756348","article-title":"Molecular pathogenesis of BCR-ABL-negative atypical chronic myeloid leukemia","volume":"11","author":"Fontana","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2023120815071758900_hem2023000448C14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"2023120815071758900_hem2023000448C15","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome I(17)(Q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"issue":"33","key":"2023120815071758900_hem2023000448C16","article-title":"SETBP1 mutations as a biomarker for myelodysplasia\/myeloproliferative neoplasm overlap syndrome","volume":"5","author":"Linder","year":"2017","journal-title":"Biomark Res"},{"issue":"9","key":"2023120815071758900_hem2023000448C17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3109\/10428194.2013.873536","article-title":"Rare occurrence of SET binding protein 1 mutation in patients with acute lymphoblastic leukemia, mixed phenotype acute leukemia and chronic myeloid leukemia in blast crisis","volume":"55","author":"Chen","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2023120815071758900_hem2023000448C18","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1046\/j.1432-1327.2001.02000.x","article-title":"Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET","volume":"268","author":"Minakuchi","year":"2001","journal-title":"Eur J Biochem"},{"issue":"pt 3","key":"2023120815071758900_hem2023000448C19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Janssens","year":"2001","journal-title":"Biochem J"},{"issue":"8","key":"2023120815071758900_hem2023000448C20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1101\/gad.1183304","article-title":"Liver tumors escape negative control of proliferation via PI3K\/Akt-mediated block of C\/EBP alpha growth inhibitory activity","volume":"18","author":"Wang","year":"2004","journal-title":"Genes Dev"},{"issue":"6615","key":"2023120815071758900_hem2023000448C21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/385454a0","article-title":"HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2\/M cell-cycle checkpoint","volume":"385","author":"Kawabe","year":"1997","journal-title":"Nature"},{"issue":"1","key":"2023120815071758900_hem2023000448C22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2007.06.034","article-title":"PP2A: unveiling a reluctant tumor suppressor","volume":"130","author":"Mumby","year":"2007","journal-title":"Cell"},{"issue":"4","key":"2023120815071758900_hem2023000448C23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2008.02.001","article-title":"Multiple pathways regulated by the tumor suppressor PP2A in transformation","volume":"14","author":"Westermarck","year":"2008","journal-title":"Trends Mol Med"},{"issue":"4","key":"2023120815071758900_hem2023000448C24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2010.294","article-title":"PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect","volume":"25","author":"Crist\u00f3bal","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2023120815071758900_hem2023000448C25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10555-008-9128-9","article-title":"A tumor suppressor role for PP2A-B56 alpha through negative regulation of C-Myc and other key oncoproteins","volume":"27","author":"Arnold","year":"2008","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2023120815071758900_hem2023000448C26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Crist\u00f3bal","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2023120815071758900_hem2023000448C27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41467-018-04462-8","article-title":"SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub","volume":"9","author":"Piazza","year":"2018","journal-title":"Nat Commun"},{"key":"2023120815071758900_hem2023000448C28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.blre.2018.07.004","article-title":"Current and evolving understanding of atypical chronic myeloid leukemia","volume":"33","author":"Schwartz","year":"2019","journal-title":"Blood Rev"},{"issue":"8","key":"2023120815071758900_hem2023000448C29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1349-7006.2012.02303.x","article-title":"Ecotropic viral integration site 1, stem cell self- renewal and leukemogenesis","volume":"103","author":"Kataoka","year":"2012","journal-title":"Cancer Sci"},{"issue":"3","key":"2023120815071758900_hem2023000448C30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023120815071758900_hem2023000448C31","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1074\/jbc.M008794200","article-title":"Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway","volume":"276","author":"Lykidis","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"2023120815071758900_hem2023000448C32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0021-9258(19)50785-2","article-title":"The function of cytidine coenzymes in the biosynthesis of phospholipides","volume":"222","author":"Kennedy","year":"1956","journal-title":"J Biol Chem"},{"issue":"1","key":"2023120815071758900_hem2023000448C33","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","article-title":"Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia","volume":"5","author":"Lasho","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023120815071758900_hem2023000448C34","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1038\/s41467-020-19721-w","article-title":"ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine","volume":"11","author":"Fontana","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"2023120815071758900_hem2023000448C35","doi-asserted-by":"crossref","first-page":"1877598","DOI":"10.1080\/23723556.2021.1877598","article-title":"Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage","volume":"8","author":"Fontana","year":"2021","journal-title":"Mol Cell Oncol"},{"issue":"9","key":"2023120815071758900_hem2023000448C36","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/leu.2017.195","article-title":"Recurrent cyclin D2 mutations in myeloid neoplasms","volume":"31","author":"Khanna","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2023120815071758900_hem2023000448C37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3324\/haematol.2020.252643","article-title":"CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients","volume":"106","author":"Cassinat","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"2023120815071758900_hem2023000448C38","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/leu.2016.332","article-title":"Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia","volume":"31","author":"Eisfeld","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2023120815071758900_hem2023000448C39","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/bloodadvances.2022008204","article-title":"CNL and aCML should be considered as a single entity based on molecular profiles and outcomes","volume":"7","author":"Carre\u00f1o-Tarragona","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2023120815071758900_hem2023000448C40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cam4.1946","article-title":"Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia","volume":"8","author":"Faisal","year":"2019","journal-title":"Cancer Med"},{"issue":"11","key":"2023120815071758900_hem2023000448C41","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2023120815071758900_hem2023000448C42","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1097\/HS9.0000000000000497","article-title":"Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia","volume":"4","author":"Fontana","year":"2020","journal-title":"Hemasphere"},{"issue":"11","key":"2023120815071758900_hem2023000448C43","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement- negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023120815071758900_hem2023000448C44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V78.1.205.205","article-title":"Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","volume":"78","author":"Martiat","year":"1991","journal-title":"Blood"},{"issue":"3","key":"2023120815071758900_hem2023000448C45","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/hon.2501","article-title":"Atypical chronic myeloid leukaemia: a case of an orphan disease-a multicenter report by the Polish Adult Leukemia Group","volume":"36","author":"Drozd-Soko\u0142owska","year":"2018","journal-title":"Hematol Oncol"},{"issue":"9","key":"2023120815071758900_hem2023000448C46","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-a-2b therapy in BCR-ABL negative myeloproliferative disorders","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"2023120815071758900_hem2023000448C47","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"2023120815071758900_hem2023000448C48","first-page":"114","article-title":"The first case of decitabine successfully in treatment of atypical chronic myeloid leukemia with CEBPA double mutation","volume":"2","author":"Mao","year":"2013","journal-title":"Chemotherapy"},{"issue":"6","key":"2023120815071758900_hem2023000448C49","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3109\/10428194.2014.986477","article-title":"Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia","volume":"56","author":"Tong","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023120815071758900_hem2023000448C50","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1078155215605662","article-title":"Activity of single-agent decitabine in atypical chronic myeloid leukemia","volume":"22","author":"Hausmann","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2023120815071758900_hem2023000448C51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3892\/ol.2015.3977","article-title":"Decitabine for the treatment of atypical chronic myeloid leukemia: a report of two cases","volume":"11","author":"Jiang","year":"2016","journal-title":"Oncol Lett"},{"issue":"19","key":"2023120815071758900_hem2023000448C52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2023120815071758900_hem2023000448C53","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"10","key":"2023120815071758900_hem2023000448C54","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.19.00895","article-title":"Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"38","author":"Dao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023120815071758900_hem2023000448C55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2023120815071758900_hem2023000448C56","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1751-553X.2011.01351.x","article-title":"Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"10","key":"2023120815071758900_hem2023000448C57","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2023120815071758900_hem2023000448C58","first-page":"e414","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna","year":"2015","journal-title":"Cureus"},{"issue":"11","key":"2023120815071758900_hem2023000448C59","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-020-00388-x","article-title":"Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points","volume":"10","author":"Gangat","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023120815071758900_hem2023000448C60","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1186\/s12885-022-10073-w","article-title":"The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocatedactive myeloid target compound combinations in MDS\/MPN overlap syndromes","volume":"22","author":"Moyo","year":"2022","journal-title":"BMC Cancer"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/476\/2175947\/476breccia.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/476\/2175947\/476breccia.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:12:19Z","timestamp":1702048339000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/476\/506467\/Atypical-CML-diagnosis-and-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000448","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}